Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs

详细信息    查看全文

• 作者：Mauro Gori^a ; Maurizio Volterrani^b ; Massimo Piepoli^c ; Michele Senni^a ; ^{msenni@hpg23.it}
• 关键词：Angiotensin receptor&ndash ; neprilysin inhibitor ; ARNi ; Heart failure ; LCZ696
• 刊名：International Journal of Cardiology
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：226
• 期：Complete
• 页码：136-140
• 全文大小：497 K
• 卷排序：226

文摘

LCZ696 is a combination drug acting as angiotensin receptor-neprilysin inhibitor In a phase 2 trial in HFpEF, LCZ696 compared to valsartan has shown superiority on surrogated outcomes According to PARADIGM-HF design, LCZ696 may replace ACEi/ARB therapy in symptomatic HFrEF patients Whether LCZ696 will replace ACEi/ARB in newly diagnosed and in HF hospitalized patients remains unclear Morbidity and mortality benefit with LCZ696 in HFpEF is being tested in the ongoing PARAGON trial